|
1
|
Li Y, Wei S, Wang J, Hong L, Cui L and
Wang C: Analysis of the factors associated with abnormal
coagulation and prognosis in patients with non-small cell lung
cancer. Zhongguo Fei Ai Za Zhi. 17:789–796. 2014.(In Chinese).
PubMed/NCBI
|
|
2
|
Sun W, Song L, Ai T, Zhang Y, Gao Y and
Cui J: Prognostic value of MET, cyclin D1 and MET gene copy number
in non-small cell lung cancer. J Biomed Res. 27:220–230.
2013.PubMed/NCBI
|
|
3
|
Molina JR, Yang P, Cassivi SD, Schild SE
and Adjei AA: Non-small cell lung cancer: Epidemiology, risk
factors, treatment, and survivorship. Mayo Clin Proc. 83:pp.
584–594. 2008; View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mirsadraee S, Oswal D, Alizadeh Y, Caulo A
and van Beek E Jr: The 7th lung cancer TNM classification and
staging system: Review of the changes and implications. World J
Radiol. 28:128–134. 2012.
|
|
5
|
Tan Z, Yang C, Zhang X, Zheng P and Shen
W: Expression of glucose transporter 1 and prognosis in non-small
cell lung cancer: A pooled analysis of 1665 patients. Oncotarget.
8:60954–60961. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhou J, Yu Y, Pei Y, Cao C, Ding C, Wang
D, Sun L and Niu G: A potential prognostic biomarker SPC24 promotes
tumorigenesis and metastasis in lung cancer. Oncotarget.
8:65469–65480. 2017.PubMed/NCBI
|
|
7
|
Geiger JL, Grandis JR and Bauman JE: The
STAT3 pathway as a therapeutic target in head and neck cancer:
Barriers and innovations. Oral Oncol. 56:84–92. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Banerjee K and Resat H: Constitutive
activation of STAT3 in breast cancer cells: A review. Int J Cancer.
138:2570–2578. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang H, Byfield G, Jiang Y, Smith GW,
McCloskey M and Hartnett ME: VEGF-mediated STAT3 activation
inhibits retinal vascularization by down-regulating local
erythropoietin expression. Am J Pathol. 180:1243–1253. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kondo S, Yoshizaki T, Wakisaka N, Horikawa
T, Murono S, Jang KL, Joab I, Furukawa M and Pagano JS: MUC1
induced by Epstein-Barr virus latent membrane protein 1 causes
dissociation of the cell-matrix interaction and cellular
invasiveness via STAT signaling. J Virol. 81:1554–1562. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gendler SJ, Lancaster CA,
Taylor-Papadimitriou J, Duhig T, Peat N, Burchell J, Pemberton L,
Lalani EN and Wilson D: Molecular cloning and expression of human
tumor-associated polymorphic epithelial mucin. J Biol Chem.
265:15286–15293. 1990.PubMed/NCBI
|
|
12
|
Jarrard JA, Linnoila RI, Lee H, Steinberg
SM, Witschi H and Szabo E: MUC1 is a novel marker for the type II
pneumocyte ineage during lung carcinogenesis. Cancer Res.
58:5582–5589. 1998.PubMed/NCBI
|
|
13
|
Ho SB, Niehans GA, Lyftogt C, Yan PS,
Cherwitz DL, Gum ET, Dahiya R and Kim YS: Heterogeneity of mucin
gene expression in normal and neoplastic tissues. Cancer Res.
53:641–651. 1993.PubMed/NCBI
|
|
14
|
Mizoguchi M, Betensky RA, Batchelor TT,
Bernay DC, Louis DN and Nutt CL: Activation of STAT3, MAPK, and AKT
in malignant astrocytic gliomas: Correlation with EGFR status,
tumor grade, and survival. J Neuropathol Exp Neurol. 65:1181–1188.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhou W, Bi X, Gao G and Sun L: miRNA-133b
and miRNA-135a induce apoptosis via the JAK2/STAT3 signaling
pathway in human renal carcinoma cells. Biomed Pharmacother.
84:722–729. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yin Z, Zhang Y, Li Y, Lv T, Liu J and Wang
X: Prognostic significance of STAT3 expression and its correlation
with chemoresistance of non-small cell lung cancer cells. Acta
Histochem. 114:151–158. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ai T, Wang Z, Zhang M, Zhang L, Wang N, Li
W and Song L: Expression and prognostic relevance of STAT3 and
cyclin D1 in non-small cell lung cancer. Int J Biol Markers.
27:e132–e138. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yu Y, Zhao Q, Wang Z and Liu XY: Activated
STAT3 correlates with prognosis of non-small cell lung cancer and
indicates new anticancer strategies. Cancer Chemother Pharmacol.
75:917–922. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang RJ, Zhang JZ and Wang P: Expression
of pSTAT3 in non-small cell lung cancer and its clinical
significance. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 28:288–290.
2012.(In Chinese). PubMed/NCBI
|
|
20
|
Xu YH and Lu S: A meta-analysis of STAT3
and phospho-STAT3 expression and survival of patients with
non-small-cell lung cancer. Eur J Surg Oncol. 40:311–317. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lavrsen K, Madsen CB, Rasch MG, Woetmann
A, Ødum N, Mandel U, Clausen H, Pedersen AE and Wandall HH:
Aberrantly glycosylated MUC1 is expressed on the surface of breast
cancer cells and a target for antibody-dependent cell-mediated
cytotoxicity. Glycoconj J. 30:227–236. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang E, Hu XF and Xing PX: Advances of
MUC1 as a target for breast cancer immunotherapy. Histol
Histopathol. 22:905–922. 2007.PubMed/NCBI
|
|
23
|
Yonezawa S, Kitajima S, Higashi M, Osako
M, Horinouchi M, Yokoyama S, Kitamoto S, Yamada N, Tamura Y,
Shimizu T, et al: A novel anti-MUC1 antibody against the MUC1
cytoplasmic tail domain: Use in sensitive identification of poorly
differentiated cells in adenocarcinoma of the stomach. Gastric
Cancer. 15:370–381. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang XT, Kong FB, Mai W, Li L and Pang LM:
MUC1 immunohistochemical expression as a prognostic factor in
gastric cancer: Meta-analysis. Dis Markers. 2016:94215712016.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang K, Tang W, Qu X, Guo Q, Inagaki Y,
Seyama Y, Abe H, Gai R, Kokudo N, Sugawara Y, et al: KL-6 mucin in
metastatic liver cancer tissues from primary colorectal carcinoma.
Hepatogastroenterology. 56:960–963. 2009.PubMed/NCBI
|
|
26
|
Mizumoto M, Honjo G, Kobashi Y, Awane M
and Matsusue S: Molecular profile of apomucin and p53 protein as
predictors of malignancy in intraductal papillary mucinous
neoplasms of the pancreas. Hepatogastroenterology. 58:1791–1795.
2011.PubMed/NCBI
|
|
27
|
Hamada T, Nomura M, Kamikawa Y, Yamada N,
Batra SK, Yonezawa S and Sugihara K: DF3 epitope expression on MUC1
mucin is associated with tumor aggressiveness, subsequent lymph
node metastasis, and poor prognosis in patients with oral squamous
cell carcinoma. Cancer. 118:5251–5264. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Leroy X, Zerimech F, Zini L, Copin MC,
Buisine MP, Gosselin B, Aubert JP and Porchet N: MUC1 expression is
correlated with nuclear grade and tumor progression in pT1 renal
clear cell carcinoma. Am J Clin Pathol. 118:47–51. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kaira K, Murakami H, Serizawa M, Koh Y,
Abe M, Ohde Y, Takahashi T, Kondo H, Nakajima T and Yamamoto N:
MUC1 expression in thymic epithelial tumors: MUC1 may be useful
marker as differential diagnosis between type B3 thymoma and thymic
carcinoma. Virchows Arch. 458:615–620. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Situ D, Wang J, Ma Y, Zhu Z, Hu Y, Long H
and Rong T: Expression and prognostic relevance of MUC1 in stage IB
non-small cell lung cancer. Med Oncol. 28 Suppl 1:S596–S604. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Demirag F, Cakir E, Bayiz H and Eren
Yazici U: MUC1 and bcl-2 expression in preinvasive lesions and
adenosquamous carcinoma of the lung. Acta Chir Belg. 113:19–24.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ahmad R, Rajabi H, Kosugi M, Joshi MD,
Alam M, Vasir B, Kawano T, Kharbanda S and Kufe D: MUC1-C
oncoprotein promotes STAT3 activation in an autoinductive
regulatory loop. Sci Signal. 4:ra92011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gao J, McConnell MJ, Yu B, Li J, Balko JM,
Black EP, Johnson JO, Lloyd MC, Altiok S and Haura EB: MUC1 is a
downstream target of STAT3 and regulates lung cancer cell survival
and invasion. Int J Oncol. 35:337–345. 2009.PubMed/NCBI
|
